Strata Critical Medical Q3 Revenue Rises 50.3% to $74.1 Million

What happened

Strata Critical Medical reported third-quarter 2026 revenue of $74.1 million, up 50.3% from a year earlier, with an operating loss of $3.8 million and a net loss of $7.6 million. The company repeated its 2026 guidance. It also announced a $20 million share repurchase authorization, which is a plan to buy back its own stock.

Confirmed

Global impact / market context

Revenue jumped mostly because of acquisitions, so the 8.5% pro forma growth shows how much sales grew without them. The company still lost money on operations, so the gap between its $9.6 million in adjusted EBITDA and its net loss shows costs like interest and accounting charges are shaping the bottom line.

Analyst inference

Strata's logistics business depends on seasonal transplant volumes, so quarterly results can swing with donor activity. The share buyback plan signals management sees room to return cash, while the repeated guidance tells investors how confident they are in future sales and profit.

Analyst inference

What to watch

1. Whether the company's full-year guidance matches its third-quarter results, and how much revenue and profit it expects for the rest of 2026. Confirmed
2. The $20 million buyback plan could reduce the number of shares, which may support profit per share if management follows through on repurchasing stock. Proposed
3. Watch logistics revenue and gross margin, which fell on seasonal transplant volume and fuel surcharge pass-through, since a rebound would lift total profit growth. Analyst inference

Evidence

• Original source link unavailable